Evaluating Zero‐Contrast Transcatheter Aortic Valve Implantation (TAVI) for Patients With Renal Impairment: A Pooled Meta‐Analysis of 1505 Patients
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70050 ↗At a glance
Metaanalyse in Catheterization and Cardiovascular Interventions, 2025. Written by Ahmed Samy Badran and 4 co-authors. Institution: Faculty of Medicine, Ain Shams University, Cairo, Egypt. Major MEDLINE topics: Aortic Valve, Aortic Valve Stenosis, Contrast Media, Kidney. 40 references. Funded by: The authors received no specific funding for this work..
Abstract (original language)
Transcatheter Aortic Valve Implantation (TAVI) is a well‐established treatment for severe aortic stenosis (AS) but poses risks for chronic kidney disease (CKD) patients due to contrast‐induced nephropathy (CIN). Zero‐contrast TAVI offers a promising alternative, though evidence on its safety and effectiveness is limited. We aim to evaluate the safety and effectiveness of zero‐contrast TAVI compared to standard TAVI in patients with AS and CKD. We followed the Cochrane Handbook and PRISMA guidelines, searching databases until September 2024. We conducted the meta‐analysis using the ‘metafor’ package with a random‐effects model, calculating mean differences (MDs) and risk ratios (RRs) along with their corresponding 95% confidence intervals (CIs). We included 1505 patients from six papers. The single‐arm meta‐analysis of zero‐contrast TAVI showed a significant implantation success rate (proportion = 0.97; 95% CI: [0.95, 0.99]; p < 0.01). Double‐arm analysis revealed no significant difference in implantation success between both groups (RR = 1.02; 95% CI: [0.97, 1.08]; p = 0.34). The postoperative mean transvalvular gradient was comparable (MD = 0.19 mmHg; 95% CI: [−0.99, 1.39]; p = 0.75). The initial pooled analysis found no significant difference in in‐hospital AKI (RR = 0.66, 95% CI: 0.20–2.17), though this was confounded by significant heterogeneity (I 2 = 71.26%). Sensitivity analysis resolved this heterogeneity and revealed a significant reduction in AKI with Zero‐contrast TAVI (RR = 0.47, 95% CI: [0.24, 0.92]; p = 0.03). Post‐procedural permanent pacemaker (PPM) implantation risk was higher in the zero‐contrast group, while Stroke rates were comparable. Zero‐contrast TAVI offers comparable success to contrast‐based approaches and potential renal benefits but carries a higher risk of PPM implantation. Trial Registration This meta‐analysis was registered on PROSPERO. No.: CRD42024597951.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Faculty of Medicine, University of Oran 1, Ahmed Ben Bella, Oran, Algeria.
- Faculty of Medicine, University of Tripoli, Tripoli, Libya.
- Faculty of Medicine, October 6 University, Giza, Egypt.
- Department of Cardiology, Egyptian Railway Medical Educational Centre, Cairo, Egypt.
ORCID profiles: Ahmed Samy Badran, Ahmed Farid Gadelmawla, Mohamed Ibrahim Gbreel
Funding
- The authors received no specific funding for this work.
Cite
APA
Badran, A. S., Gadelmawla, A. F., Khelifa, H., Hasanin, E. H., & Gbreel, M. I. (2025). Evaluating Zero‐Contrast Transcatheter Aortic Valve Implantation (TAVI) for Patients With Renal Impairment: A Pooled Meta‐Analysis of 1505 Patients. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70050
Vancouver
Badran AS, Gadelmawla AF, Khelifa H, Hasanin EH, Gbreel MI. Evaluating Zero‐Contrast Transcatheter Aortic Valve Implantation (TAVI) for Patients With Renal Impairment: A Pooled Meta‐Analysis of 1505 Patients. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70050
BibTeX
@article{Badran2025,
author = {Badran, Ahmed Samy and Gadelmawla, Ahmed Farid and Khelifa, Hamza and Hasanin, Ekram Hassan and Gbreel, Mohamed Ibrahim},
title = {Evaluating Zero‐Contrast Transcatheter Aortic Valve Implantation (TAVI) for Patients With Renal Impairment: A Pooled Meta‐Analysis of 1505 Patients},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70050}
}
EUVIMED